COVOVAX Archives

Covovax Review: NTAGI’s Working Group To Review New Serum Vaccine

Gunjan ChaudharyMarch 30, 20220

The COVID-19 working group of the National Technical Advisor (NTAGI) will review the new corona vaccine 'Covovax' developed by the Serum Institute of India (SII). This vaccine is designed for children and adults specifically. And the review meeting will be held on April 1. The NTAGI set up for Immunization has a three-tier system to decide on a vaccine. This working group is of the first level review. A second-level Standing Technical Sub-Committee (STSC) will review and discuss the safety and effectiveness of the vaccine data after the working group looks at the safety and effectiveness of the vaccine data. Thereafter, STSC will give its decision to the third group to make the final decision. Booster Dose Is Not For Everyone In the meeting to be held on Friday, NTAGI will not discu...

COVID-19EducationHealthHotIndiaLatest NewsLifestyleScience & TechSocietyTrendingVaccine

India’s Vaccination Drive Adds Children Of 12 -14 years with CORBEVAX.

Sonia SolankiMarch 15, 20220

India's vaccination Drive adds another important group in its feather. This group includes children aged between 12 -14 years. Now, children between this age group will get jabs from 16th March onwards. Corbevax is the choice of vaccination for this age group. The Union Health Minister, Mr. Mansukh Mandaviya, says that "If children are safe, then the country is safe. I am happy to announce that from March 16, covid vaccination will start for children belonging to the age group of 12 -14 years". He also informed that with this addition we will be giving 6 to 6.5 crore doses to the youngsters. Vaccination Drive For Youngsters : There are no two ways that vaccinating such a humungous population needs many steps and processes to achieve the protection cover for all. So, far though...

COVID-19HealthIndiaNewsVaccine

COVOVAX Vaccine By Serum Institute of India Gets Emergency Approval From WHO

Sonia SolankiDecember 20, 20210

Covovax Vaccine by the Serum Institute of India [SII] gets the approval from the WHO for emergency use. Under the license from Novavax, Covovax will be produced in India by the SII. It is a part of COVAX, a worldwide initiative aimed at providing, equitable access to COVID-19 vaccines. Moving ahead in this direction the WHO issuing emergency use listing of the Covovax is a step in expanding the basket of jabs validated by the global health body against Corona. As a result of this step by the WHO Covovax becomes the 9th vaccine to be listed. Meanwhile Adar Poonawalla tweets, "This is yet another milestone in our fight against COVID-19, showing excellent safety and efficacy. Thank you all for a great collaboration." Indeed its a great news among the rising cases of Omicron variant across...